The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

The European Medicines Agency has announced the commencement of an evaluation for the extension of use of Comirnaty, Pfizer/BioNTech’s COVID-19 vaccine, to include young people aged 12 to 15 years.

Accelerated Assessment of Comirnaty in Young People Commences

The European Medicines Agency’s Committee for Medicinal Products for Human Use has started a rolling review of Vero Cell, an inactivated COVID-19 vaccine developed by Sinovac Life Sciences. 

EMA’s CHMP Starts Rolling Review of Inactivated COVID-19 Vaccine

Vectura and Inspira Pharmaceuticals have joined forces to develop a potential inhaled therapy for COVID-19.

Vectura, Inspira Pharmaceuticals Team Up to Develop Potential Inhaled COVID-19 Treatment

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Combating COVID-19 is bolstering efforts to limit patent protections on innovative medicines and vaccines.

Pharma Prices and Patents Under Attack

Moderna will double the space at its Moderna Technology Center in Norwood, MA, to transform it from a production and lab space into an industrial technology center. 

Moderna to Expand its Massachusetts Manufacturing Technology Center

Moderna has entered into an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of its COVID-19 vaccine to the 92 Gavi COVAX Advance Market Commitment low- and middle-income countries. 

Moderna to Supply Up to 500 Million COVID-19 Vaccine Doses to Low- and Middle-Income Countries

Under the terms of the contract, Meissner will expand its Camarillo, Calif., manufacturing site by adding additional cleanroom manufacturing space, executing advanced inventory management systems, and adding support areas to supplement capacity.

Meissner Filtration Products Awarded Contract from BARDA for COVID-19 Production Capacity Expansion

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

As face masks start to come off, bio/pharma’s COVID-19 battle goes on.

Moving Into the Next Phase

The European Medicines Agency and the European Centre for Disease Prevention  have joined forces in a new initiative aimed at strengthening the post-marketing surveillance of COVID-19 vaccines in Europe.

EMA, ECDC Team Up to Strengthen Post-Marketing Surveillance of COVID-19 Vaccines

Moderna’s investments will double the formulation fill/finish and drug substance manufacturing of its vaccine to up to three billion doses in 2022 at various manufacturing sites. 

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success